Galena Biopharma Inc. (GALE)

5.72
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 5.72
Open 5.72
Day Low/High 5.56 / 5.85
52 Wk Low/High 3.43 / 19.80
Volume 55.42K
Avg Volume 886.60K
Exchange NASDAQ
Shares Outstanding 45.71M
Market Cap 11.98M
EPS -2,128.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Galena Biopharma (GALE) In A Perilous Reversal

Galena Biopharma (GALE) In A Perilous Reversal

Trade-Ideas LLC identified Galena Biopharma (GALE) as a "perilous reversal" (up big yesterday but down big today) candidate

January 2016 Options Now Available For Galena Biopharma (GALE)

January 2016 Options Now Available For Galena Biopharma (GALE)

Investors in Galena Biopharma Inc saw new options become available today, for the January 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 784 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ratings Changes Today

Upgrades: AGO, BBGI, BKMU, CODI, EME, FONR, LPI Downgrades: ADNC, AUQ, CYD, DATE, DPZ, EROC, FSP, LBTYB, LBTYK, LYV, NPSP, RLJ, SF, SHO Initiations: ANFI, GALE, RLGY Read on to get TheStreet Quant Ratings' detailed report:

2 Biotech Stocks Under $10 to Watch

2 Biotech Stocks Under $10 to Watch

Keep these under-$10 biotech stocks on your radar.

First Week Of December 21st Options Trading For Galena Biopharma (GALE)

First Week Of December 21st Options Trading For Galena Biopharma (GALE)

Investors in Galena Biopharma Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALE options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Galena Biopharma Launches Abstral(R) (fentanyl) Sublingual Tablets For The Treatment Of Breakthrough Cancer Pain

Galena Biopharma Launches Abstral(R) (fentanyl) Sublingual Tablets For The Treatment Of Breakthrough Cancer Pain

First Commercial Product for Galena Biopharma Available Nationwide

Biotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice Mail

Biotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice Mail

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.